Shares of Avadel Pharmaceuticals PLC AVDL, -62.72% tumbled 21.6% in premarket trading on Thursday after the company said in a securities filing that the Food and Drug Administration requested additional information for its experimental narcolepsy drug. Avadel said it now expects to get a FDA decision on the drug, FT218, by June of next year. The company’s stock is down 58.1% this year, while the S&P 500 SPX, +2.25% has declined 16.5%.
View Article Origin Here
